Have an account? Log in.
I don't have an account.
Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.
Robert F. Kennedy Jr. unveiled a federal initiative to curb the overuse of psychiatric medications, emphasizing deprescribing and a shift toward preventive, patient-centered mental health care.
Bristol-Myers Squibb beats Q1 2026 estimates as growth drugs lift revenue, while the legacy portfolio faces continued generic pressure.
Investors turn to dividend-yielding stocks during market turbulence. Benzinga's database offers accurate analyst ratings on high-yield stocks in healthcare sector.
Bristol-Myers Squibb (NYSE:BMY) affirms FY2026 Adj EPS guidance from $6.05-$6.35 to $6.05-$6.35 vs $6.27 analyst estimate. Affirms FY2026 sales outlook from $46.000 billion-$47.500 billion to $46.000 billion-$47.500
Bristol-Myers Squibb (NYSE:BMY) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $1.42 by 11.27 percent. This is a 12.22 percent decrease over earnings of $1.80 per share from
Expands Options for Cash-Paying Patients to Access the Nation's #1 Prescribed Oral Blood ThinnerThe Bristol Myers Squibb-Pfizer (NYSE:BMY) — (NYSE:PFE) Alliance today announced the launch of a collaboration with Mark